Lexeo Therapeutics (LXEO) EBIT: 2022-2024
Historic EBIT for Lexeo Therapeutics (LXEO) over the last 3 years, with Dec 2024 value amounting to -$105.8 million.
- Lexeo Therapeutics' EBIT rose 1.47% to -$15.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$68.5 million, marking a year-over-year change of. This contributed to the annual value of -$105.8 million for FY2024, which is 54.37% down from last year.
- Latest data reveals that Lexeo Therapeutics reported EBIT of -$105.8 million as of FY2024, which was down 54.37% from -$68.5 million recorded in FY2023.
- In the past 5 years, Lexeo Therapeutics' EBIT registered a high of -$60.5 million during FY2022, and its lowest value of -$105.8 million during FY2024.
- In the last 3 years, Lexeo Therapeutics' EBIT had a median value of -$68.5 million in 2023 and averaged -$78.3 million.
- Data for Lexeo Therapeutics' EBIT shows a maximum YoY plummeted of 54.37% (in 2024) over the last 5 years.
- Over the past 3 years, Lexeo Therapeutics' EBIT (Yearly) stood at -$60.5 million in 2022, then decreased by 13.23% to -$68.5 million in 2023, then slumped by 54.37% to -$105.8 million in 2024.